13 Recruiting Breast Neoplasms Phase 2 Clinical Trials
Active phase 2 studies for breast neoplasms enrolling across the USA. Verify eligibility and contact site coordinators.
All Breast Neoplasms studiesPhase 2 Studies for Breast Neoplasms
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
📍 Mayo Clinic Arizona — Phoenix, Arizona
View Study & Checklist ➔Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer
📍 10 sites incl TX, WA, VA, and NV — Dallas, Texas
View Study & Checklist ➔A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
📍 Banner-University Medical Center Tucson Campus — Tucson, Arizona
View Study & Checklist ➔Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer
📍 City of Hope Medical Center — Duarte, California
View Study & Checklist ➔Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast
📍 Mount Sinai Beth Israel Comprehensive Cancer Center West — New York, New York
View Study & Checklist ➔PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer
📍 University of Alabama — Birmingham, Alabama
View Study & Checklist ➔Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM
📍 Rhode Island and the Miriam Hospitals (Brown University Health) — Providence, Rhode Island
View Study & Checklist ➔Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
📍 Providence Medical Foundation — Fullerton, California
View Study & Checklist ➔I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
📍 University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
📍 University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
📍 UCLA Hematology/Oncology - Parkside ( Site 0021) — Santa Monica, California
View Study & Checklist ➔A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
📍 Local Institution - 0303 — Hot Springs, Arkansas
View Study & Checklist ➔Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
📍 University of Colorado Anschutz Medical Campus ( Site 0057) — Aurora, Colorado
View Study & Checklist ➔